ZA200705943B - Survivin peptide vaccine - Google Patents

Survivin peptide vaccine

Info

Publication number
ZA200705943B
ZA200705943B ZA200705943A ZA200705943A ZA200705943B ZA 200705943 B ZA200705943 B ZA 200705943B ZA 200705943 A ZA200705943 A ZA 200705943A ZA 200705943 A ZA200705943 A ZA 200705943A ZA 200705943 B ZA200705943 B ZA 200705943B
Authority
ZA
South Africa
Prior art keywords
peptide vaccine
survivin peptide
survivin
vaccine
peptide
Prior art date
Application number
ZA200705943A
Other languages
English (en)
Inventor
Andersen Mads Hald
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Publication of ZA200705943B publication Critical patent/ZA200705943B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200705943A 2005-02-04 2006-02-03 Survivin peptide vaccine ZA200705943B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500173 2005-02-04

Publications (1)

Publication Number Publication Date
ZA200705943B true ZA200705943B (en) 2008-12-31

Family

ID=39042995

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705943A ZA200705943B (en) 2005-02-04 2006-02-03 Survivin peptide vaccine

Country Status (16)

Country Link
US (1) US20110091489A1 (ru)
EP (3) EP1853305B1 (ru)
JP (2) JP2008528643A (ru)
KR (1) KR20070108536A (ru)
CN (3) CN103143004A (ru)
AU (1) AU2006209951B2 (ru)
BR (1) BRPI0607326B8 (ru)
CA (1) CA2593714C (ru)
DK (1) DK1853305T3 (ru)
ES (1) ES2523172T3 (ru)
HK (1) HK1112367A1 (ru)
MX (1) MX2007009219A (ru)
PL (1) PL1853305T3 (ru)
RU (1) RU2396088C2 (ru)
WO (1) WO2006081826A2 (ru)
ZA (1) ZA200705943B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2009106073A2 (en) * 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
JP2011520783A (ja) 2008-04-17 2011-07-21 エルレフ ホスピタル インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
FR2955776A1 (fr) * 2010-02-01 2011-08-05 Seppic Sa Utilisation d'une huile minerale specifique pour la fabrication d'un nouveau adjuvant
FR2955775B1 (fr) * 2010-02-01 2012-05-04 Seppic Sa Adjuvant pour la preparation de compositions vaccinales destinees a la prevention contre les coccidioses
EP3912634B1 (en) 2012-05-16 2023-10-04 Stemline Therapeutics Inc. Cancer stem cell targeted cancer vaccines
CA2908042C (en) 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
CN105873941A (zh) * 2013-12-16 2016-08-17 默克专利有限公司 生存素导向的癌症疫苗治疗
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
JP6989134B2 (ja) 2015-11-18 2022-01-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
TWI628189B (zh) * 2016-02-23 2018-07-01 財團法人國家衛生研究院 脂質化存活素（ｓｕｒｖｉｖｉｎ）及其用以預防及治療癌症之用途
MX2019002968A (es) 2016-09-21 2019-10-15 Amal Therapeutics Sa Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal.
CN107228894B (zh) * 2017-01-24 2019-03-19 浙江海隆生物科技有限公司 一种油乳剂蛋白亚单位疫苗中蛋白含量和纯度的检测方法及其应用
MX2019010459A (es) 2017-03-03 2020-01-09 Treos Bio Zrt Vacuna.
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
WO2019133853A1 (en) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
MX2021002449A (es) 2018-09-04 2021-08-05 Treos Bio Ltd Vacunas peptidicas.
WO2020104923A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP0662839A4 (en) * 1992-09-30 1995-09-06 Univ Ohio State Res Found ANTIGENIC VACCINES AND CONJUGATES.
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
AU736587B2 (en) 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US20030104570A1 (en) * 2000-06-26 2003-06-05 Cabezon Silva Teresa Elisa Virginia Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
EP2027867A1 (en) * 2000-10-20 2009-02-25 Genetics Institute, LLC Method and composition for inhibition of tumor growth and enhancing an immune response
JP2002365286A (ja) * 2000-11-13 2002-12-18 Kyogo Ito 細胞性免疫検出法およびその医薬への応用
JP4780540B2 (ja) * 2001-03-23 2011-09-28 北海道公立大学法人 札幌医科大学 サバイビン由来癌抗原ペプチド
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US6780121B2 (en) * 2002-09-09 2004-08-24 Paul J. Herber Golf club head construction
JP4611022B2 (ja) * 2002-09-12 2011-01-12 株式会社癌免疫研究所 癌抗原ペプチド製剤
US7221826B2 (en) * 2002-10-08 2007-05-22 Tdk Corporation Spot-size transformer, method of producing spot-size transformer and waveguide-embedded optical circuit using spot-size transformer
CA2508302A1 (en) * 2002-12-02 2004-06-17 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment
WO2004063217A1 (ja) * 2003-01-15 2004-07-29 Chugai Seiyaku Kabushiki Kaisha 二量体化ペプチド
EP2343083B1 (en) * 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
DE602004019965D1 (de) * 2003-11-19 2009-04-23 Survac Aps Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten

Also Published As

Publication number Publication date
BRPI0607326B8 (pt) 2021-05-25
RU2396088C2 (ru) 2010-08-10
HK1112367A1 (en) 2008-08-29
EP1853305B1 (en) 2014-08-20
US20110091489A1 (en) 2011-04-21
CN101111260B (zh) 2013-03-20
JP5631357B2 (ja) 2014-11-26
ES2523172T3 (es) 2014-11-21
JP2008528643A (ja) 2008-07-31
CA2593714C (en) 2013-09-10
BRPI0607326B1 (pt) 2021-01-19
EP1853305A2 (en) 2007-11-14
CA2593714A1 (en) 2006-08-10
MX2007009219A (es) 2008-01-16
KR20070108536A (ko) 2007-11-12
AU2006209951A1 (en) 2006-08-10
WO2006081826A3 (en) 2007-02-15
WO2006081826A2 (en) 2006-08-10
CN103143004A (zh) 2013-06-12
PL1853305T3 (pl) 2015-02-27
BRPI0607326A2 (pt) 2009-09-01
DK1853305T3 (en) 2014-12-01
AU2006209951B2 (en) 2011-04-14
RU2007133103A (ru) 2009-03-10
CN101111260A (zh) 2008-01-23
CN103169958A (zh) 2013-06-26
EP2329840A1 (en) 2011-06-08
EP2329841A1 (en) 2011-06-08
JP2012149101A (ja) 2012-08-09

Similar Documents

Publication Publication Date Title
ZA200705943B (en) Survivin peptide vaccine
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
IL219048A (en) Peptide compounds derived from urcl10
GB0508863D0 (en) Peptide
ZA200803525B (en) New cyclic peptide compounds
ZA200802571B (en) GDNF derived peptides
GB0805675D0 (en) Adjuvanted vaccine
GB0515135D0 (en) Vaccine
ZA200709207B (en) Vaccine
GB2443591B (en) Adjuvanted vaccine
GB0526019D0 (en) Peptides
GB0516527D0 (en) Peptides
GB0516944D0 (en) Vaccine
EP1939286A4 (en) NEW PEPTIDE
GB0810662D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0526412D0 (en) Vaccine
GB0512969D0 (en) Peptides
GB0523953D0 (en) Peptides
GB0513194D0 (en) Vaccine
GB0521164D0 (en) Vaccine
GB0503000D0 (en) Anti-atheroma vaccine
GB0511475D0 (en) Vaccine
GB0513189D0 (en) Vaccine